Vericel Corp (VCEL) – Strategy, SWOT and Corporate Finance Report

Vericel Corp (VCEL) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal burns. The company has manufacturing facility in Cambridge, Massachusetts and sells its products to sports medicine orthopedic surgeons and specialized burn centers through cell therapy specialists in the US. Vericel is headquartered in Cambridge, Massachusetts, the US.

Scope

• Detailed information on Vericel Corp required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Vericel Corp in the form of a SWOT analysis

• An in-depth view of the business model of Vericel Corp including a breakdown and examination of key business segments

• News about Vericel Corp, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Vericel Corp and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Vericel Corp as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Vericel Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Aesculap Biologics LLC

AlloSource

Anika Therapeutics Inc

Arthrex Inc

Avita Medical Americas LLC

Stryker Corp

Zimmer Biomet Holdings Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Vericel Corp - Key Facts

Vericel Corp - Key Employees

Vericel Corp - Key Employee Biographies

Vericel Corp - Major Products and Services

Vericel Corp - History

Vericel Corp - Company Statement

Vericel Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Vericel Corp - Business Description

Product Category: Epicel

Overview

Performance

Product Category: MACI

Overview

Performance

Product Category: NexoBrid

Overview

Performance

R&D Overview

Vericel Corp - Corporate Strategy

Vericel Corp - SWOT Analysis

SWOT Analysis - Overview

Vericel Corp - Strengths

Vericel Corp - Weaknesses

Vericel Corp - Opportunities

Vericel Corp - Threats

Vericel Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Vericel Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Vericel Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jan 10, 2023: Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

Nov 09, 2022: Vericel Reports Third Quarter 2022 Financial Results

Aug 03, 2022: Vericel Reports Second Quarter 2022 Financial Results

May 04, 2022: Vericel Reports First Quarter 2022 Financial Results

Feb 24, 2022: Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance

Feb 24, 2022: Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer

Feb 02, 2022: Vericel announces plans for a new state-of-the-art cell therapy manufacturing facility to support long-term growth

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Vericel Corp, Key Facts

Vericel Corp, Key Employees

Vericel Corp, Key Employee Biographies

Vericel Corp, Major Products and Services

Vericel Corp, History

Vericel Corp, Other Locations

Vericel Corp, Subsidiaries

Vericel Corp, Key Competitors

Vericel Corp, Ratios based on current share price

Vericel Corp, Annual Ratios

Vericel Corp, Annual Ratios (Cont…1)

Vericel Corp, Annual Ratios (Cont…2)

Vericel Corp, Interim Ratios

Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Vericel Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Vericel Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Vericel Corp, Performance Chart (2018 – 2022)

Vericel Corp, Ratio Charts

Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Vericel Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports